RSS Items

Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year

Pharma group behind blockbuster drug wants to supersize its market impact

Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema

People treated with amycretin lost up to 22% of their body weight after 36 weeks

Obesity treatment CagriSema misses goal of 25% reduction in body weight

Danish manufacturer Wegovy invests in two start-ups as part of efforts to stay ahead in major new market

Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment

Chief executive says customers very willing to pay for Wegovy from their own pockets

Market will never be winner takes all given that different patients will have different requirements

Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group